Comparison of gene expression between natural ligand treatment and agonistic antibody treatment in a CD30+ cell line

CD30 receptor (TNFRSF8) is highly expressed in some types of lymphoma. CD30 is successfully used as a target for antibody-drug conjugate to treat CD30+ lymphoma. The agonistic activity of the anti-CD30 antibody likely contributes to tumor cell killing. However, not all antibodies exhibit agonistic activity. We found that potent agonistic antibodies recognize the N-terminus epitope cluster that is distantly located from the ligand binding site of CD30. This study compared gene expression profiles between CD30 natural ligand and agonistic antibody T104 treatment in a CD30+ ALCL Karpas 299 cell line. 8 samples were analyzed. CD30+ ALCL Karpas 299 cells were precultured for 16 hrs. They were subsequently treated in the used medium with CD153(CD30L)-Fc fusion protein and/or anti-CD30 agonistic T104 monoclonal antibodies for 8 hrs. Biological duplicates were prepared for (1) untreated cells, (2) CD153-Fc-treated cells, (3) T104-treated cells, (4) CD153-Fc plus T104-treated cells. Biotin-labeled cRNA was prepared from the total RNA and subjected to hybridization with the HumanHT-12 v3 Expression BeadChip (Illumina). Data were analyzed using BeadStudio.